Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3765581015 | Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 3765582010 | Product containing precisely hydrocortisone acetate 15 milligram/1 milliliter and neomycin (as neomycin sulfate) 5 milligram/1 milliliter conventional release eye solution (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has concentration strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has concentration strength denominator unit | mL | true | Inferred relationship | Some | 2 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has concentration strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has concentration strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Count of base of active ingredient | 2 | false | Inferred relationship | Some | ||
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has concentration strength denominator unit | mL | true | Inferred relationship | Some | 1 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has concentration strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has manufactured dose form | Conventional release eye solution (dose form) | true | Inferred relationship | Some | ||
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Is a | Product containing only hydrocortisone and neomycin in ocular dose form (medicinal product form) | true | Inferred relationship | Some | ||
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has concentration strength numerator value | 5 | false | Inferred relationship | Some | 1 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has precise active ingredient | Neomycin sulfate | true | Inferred relationship | Some | 1 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has precise active ingredient | Hydrocortisone acetate | true | Inferred relationship | Some | 2 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has concentration strength numerator value | 15 | false | Inferred relationship | Some | 2 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has basis of strength substance (attribute) | Hydrocortisone acetate | true | Inferred relationship | Some | 2 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Has basis of strength substance (attribute) | Neomycin (substance) | true | Inferred relationship | Some | 1 | |
| Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution | Plays role | Antibacterial therapeutic role (role) | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR